16 September 2026 editorial review · Item
Cadisegliatin (oral glucokinase activator): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Cadisegliatin (oral glucokinase activator)
Scope and findings:
- Live status/dates150,CATT1active-notrecruitingApril2027,Hybrid40notyetrecruitingApril2027 compared againstAug6companyQ3enrollment/yearendHybridguidance. No new efficacy readout found on current sponsor press list; old phase 2 efficacy not rechecked.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.